Avid, GHO and Ampersand

This week, biologics CDMO Avid Bioservices revealed that it’s agreed to be acquired by funds managed by Ampersand and ...
The merger agreement is valued at approximately $1.1 billion. Avid Bioservices, a biologics contract development and manufacturing organization (CDMO), announced on Nov. 6, 2024 that it has entered ...
Avid “operates in high-growth markets, producing complex biologics for leading pharmaceutical and biotech innovators at both ...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Avid Bioservices, Inc. (NASDAQ: CDMO) to funds managed by GHO Capital Partners LLP and Ampersand Capital Partners ...
Avid Bioservices (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners announced they have entered into a definitive merger agreement for Avid to be acquired by funds managed by GHO ...